Partnership Opportunities
Partnership with Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye. Using our proprietary bioresorbable hydrogel-based formulation technology ELUTYX™, we are advancing the field of ophthalmology by addressing critical unmet needs in eye care.
Areas of Interest
We are interested in licensing or acquiring ophthalmology assets consistent with our corporate strategy to
broaden our portfolio. Our areas of interest include:
Leaders in Development
As a leader in the development of innovative treatments for ophthalmic diseases, we welcome discussions with key partners to enable the expansion of patient care options in the field. We are open to scientific, research, and commercial partnerships of our products and drug delivery technologies.
Current Partnerships
We are open to partnerships for our product candidates outside of the United States. We currently have a partnership with AffaMed for the development and commercialization of two of our product candidates, DEXTENZA® (dexamethasone ophthalmic insert) and OTX-TIC* (travoprost intracameral hydrogel), in Greater China, South Korea, and the ASEAN markets.
*PAXTRAVA™ (travoprost intracameral hydrogel), also referenced as laboratory code OTX-TIC
Find out more about partnerships
If you are interested in finding out more about partnerships, contact a member of our corporate development team at bd@ocutx.com.